Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

NGNE

Live52w high -20.0%

Annual Quarterly

Core line items from NGNE's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: Neurogene Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Annual 2024 2024-12-31
Revenue	$0.00	$0.00	$0.00	$0.00	$925.00K
Operating Income	Not available	$-103.33M	$-75.80M	$-52.00M	$-82.61M
Net Income	Not available	$-90.35M	$-65.62M	$-22.02M	$-75.14M
EPS (Diluted)	$-1.40	$-4.24	$-3.11	$-2.12	$-4.28
Total Assets	Not available	$288.60M	$287.83M	$297.32M	$335.73M
Total Liabilities	Not available	$23.72M	$22.29M	$24.06M	$25.36M
Cash & Equivalents	Not available	$103.84M	$71.00M	$58.81M	$136.59M
Free Cash Flow OCF − CapEx	Not available	$-78.36M	$-60.80M	$-41.16M	$-71.41M
Shares Outstanding	Not available	15.49M	14.78M	14.27M	14.85M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from NGNE's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -20.0%

Entity: Neurogene Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Annual 2024 2024-12-31
Revenue	$0.00	$0.00	$0.00	$0.00	$925.00K
Operating Income	Not available	$-103.33M	$-75.80M	$-52.00M	$-82.61M
Net Income	Not available	$-90.35M	$-65.62M	$-22.02M	$-75.14M
EPS (Diluted)	$-1.40	$-4.24	$-3.11	$-2.12	$-4.28
Total Assets	Not available	$288.60M	$287.83M	$297.32M	$335.73M
Total Liabilities	Not available	$23.72M	$22.29M	$24.06M	$25.36M
Cash & Equivalents	Not available	$103.84M	$71.00M	$58.81M	$136.59M
Free Cash Flow OCF − CapEx	Not available	$-78.36M	$-60.80M	$-41.16M	$-71.41M
Shares Outstanding	Not available	15.49M	14.78M	14.27M	14.85M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.